Devyser Diagnostics AB (DVYSR)

Stockholm
Currency in SEK
129.80
-5.00(-3.71%)
Closed·
DVYSR Scorecard
Full Analysis
Liquid assets exceed short term obligations
Earnings results expected in 10 days
Fair Value
Day's Range
128.60138.80
52 wk Range
83.30145.00
Key Statistics
Edit
Prev. Close
134.8
Open
137.2
Day's Range
128.6-138.8
52 wk Range
83.3-145
Volume
23.76K
Average Volume (3m)
30.87K
1-Year Change
15.89%
Book Value / Share
19.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DVYSR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
159.99
Upside
+23.26%
Members' Sentiments
Bearish
Bullish
ProTips
Not profitable over the last twelve months

Devyser Diagnostics AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Devyser Diagnostics AB Company Profile

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is based in Årsta, Sweden.

Employees
120
Market
Sweden

Devyser Diagnostics AB Earnings Call Summary for Q1/2025

  • Devyser Diagnostics Q1 2025 revenue up 8% YoY to 55M SEK; EBIT negative at -21M SEK due to restructuring costs and FX headwinds
  • Company maintains 30% organic growth target for 2025; plans new product launches in transplantation diagnostics
  • FDA program and MolDX reimbursement application in U.S. signal potential market expansion
  • Interim CEO emphasizes focus on leveraging investments, organizational efficiency, and path to profitability
  • Analysts maintain 'Buy' rating with upside potential, despite current stock overvaluation based on Fair Value calculations
Last Updated: 29/04/2025, 07:54 pm
Read Full Transcript

Compare DVYSR to Peers and Sector

Metrics to compare
DVYSR
Peers
Sector
Relationship
P/E Ratio
−30.9x2.3x−0.5x
PEG Ratio
0.62−0.080.00
Price/Book
6.5x5.3x2.6x
Price / LTM Sales
9.7x30.9x3.2x
Upside (Analyst Target)
21.7%23.1%45.4%
Fair Value Upside
Unlock9.8%6.9%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 159.99
(+23.26% Upside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
-1.24 / -0.4033
Revenue / Forecast
54.75M / 57.18M
EPS Revisions
Last 90 days

DVYSR Income Statement

FAQ

What Is the Devyser Diagnostics AB (DVYSR) Stock Price Today?

The Devyser Diagnostics AB stock price today is 129.80

What Stock Exchange Does Devyser Diagnostics AB Trade On?

Devyser Diagnostics AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Devyser Diagnostics AB?

The stock symbol for Devyser Diagnostics AB is "DVYSR."

What Is the Devyser Diagnostics AB Market Cap?

As of today, Devyser Diagnostics AB market cap is 2.15B.

What Is Devyser Diagnostics AB's Earnings Per Share (TTM)?

The Devyser Diagnostics AB EPS (TTM) is -4.24.

When Is the Next Devyser Diagnostics AB Earnings Date?

Devyser Diagnostics AB will release its next earnings report on 22 July 2025.

From a Technical Analysis Perspective, Is DVYSR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Devyser Diagnostics AB Stock Split?

Devyser Diagnostics AB has split 0 times.

How Many Employees Does Devyser Diagnostics AB Have?

Devyser Diagnostics AB has 120 employees.

What is the current trading status of Devyser Diagnostics AB (DVYSR)?

As of 12 July 2025, Devyser Diagnostics AB (DVYSR) is trading at a price of 129.80, with a previous close of 134.80. The stock has fluctuated within a day range of 128.60 to 138.80, while its 52-week range spans from 83.30 to 145.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.